MMR Inhibitor Program
MMR-Proficient Solid Tumors (e.g., Colorectal, Endometrial, Gastric Cancers)
Pre-clinicalActive
Key Facts
Indication
MMR-Proficient Solid Tumors (e.g., Colorectal, Endometrial, Gastric Cancers)
Phase
Pre-clinical
Status
Active
Company
About NeoPhore
NeoPhore is pioneering a novel immuno-oncology approach by pharmacologically inducing a transient state of MMR deficiency in tumors to unlock immunotherapy responses. Founded on seminal academic research, the company has developed a platform to discover small molecule MMR inhibitors and has validated its hypothesis in preclinical models. Backed by a strong syndicate of life science investors, including Bristol Myers Squibb, NeoPhore is advancing towards clinical testing with the goal of significantly broadening patient access to transformative cancer immunotherapies.
View full company profile